Company / R&D Expense
PUMA BIOTECHNOLOGY, INC. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$50.4M
FY2025
5-year range
$50.4M / $132.9M
FY2021-FY2025
Trend
-3.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 7 consecutive years, from $223M in FY2018 to $50M in FY2025.
Based on SEC 10-K filings.
$50M in FY2025 with a 5-year CAGR of -21.1%.
Declined from $72M to $50M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -19.8%
- 5-Year CAGR
- -21.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- PUMA BIOTECHNOLOGY, INC.'s r&d expense has declined for 7 consecutive years.
- 5-year CAGR of -21.1%, indicating a declining trend.
- In FY2025, r&d expense decreased 3.6% year-over-year.
- Peak r&d expense was recorded in FY2018.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.4M | -3.6% |
| FY2024 | $52.2M | -27.3% |
| FY2023 | $71.9M | -26.4% |
| FY2022 | $97.7M | -26.5% |
| FY2021 | $132.9M | -19.4% |
| FY2020 | $164.9M | -20.7% |
| FY2019 | $207.8M | -6.7% |
| FY2018 | $222.8M | +6.9% |
| FY2017 | $208.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026